Literature DB >> 9204612

Frequency of intestinal parasites in adult cancer patients in Mexico.

J Guarner1, T Matilde-Nava, R Villaseñor-Flores, G Sanchez-Mejorada.   

Abstract

Approximately 28% of the Mexican population has intestinal parasites. Oncologic patients receiving chemotherapy should have a coproparasitoscopic study to avoid disseminated parasitic infections. The frequency of intestinal parasites, including Cryptosporidium and Isospora, was evaluated in 100 diarrheic (DS) and 100 formed stools (FS) from adult patients recently diagnosed with cancer, using wet mounts stained with Kinyoun, saccharose and ZnSO4 procedures stained with Lugol's iodine. Seven patients with DS and three with FS had more than one parasite. Pathogenic intestinal parasites were seen in 26% of DS and 15% of FS. Of the frequent parasites, Entamoeba histolytica was found in 12 DS and in 2 FS (p = 0.01), Giardia lamblia in three DS and six FS and Hymenolepis nana in eight DS and 10 FS. Other pathogenic parasites were found only in DS: Cryptosporidium sp. in five patients, Ascaris lumbricoides in two, Strongyloides stercoralis in two and Isospora sp. in one. Cryptosporidium and Isospora were only identified by wet mounts stained with Kinyoun while other parasites were identified by flotation procedures. Since six (3%) of our patients had coccidia, the laboratory must perform special techniques for their detection. In epidemiologic settings where there is a high prevalence of intestinal parasitic infections the coproparasitoscopic studies should be performed and antiparasitic treatment provided before starting chemotherapy.

Entities:  

Mesh:

Year:  1997        PMID: 9204612

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  8 in total

1.  Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies.

Authors:  Adrián Sánchez-Montalvá; Fernando Salvador; Isabel Ruiz-Camps; Pere Barba; David Valcárcel; Elena Sulleiro; Enrique Sanz-García; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2016-10-17       Impact factor: 2.345

2.  Prevalence and associated risk factors of Cystoisospora belli and Cyclospora cayetanensis infection among Iranian patients with colorectal cancer.

Authors:  Hossein Mahmoudvand; Akram Sepahvand; Mehrdad Khatami; Alireza Moayyedkazemi
Journal:  J Parasit Dis       Date:  2019-03-19

Review 3.  Strongyloidiasis--an insight into its global prevalence and management.

Authors:  Santhosh Puthiyakunnon; Swapna Boddu; Yiji Li; Xiaohong Zhou; Chunmei Wang; Juan Li; Xiaoguang Chen
Journal:  PLoS Negl Trop Dis       Date:  2014-08-14

4.  Microbial Signatures Associated with Oropharyngeal and Oral Squamous Cell Carcinomas.

Authors:  Sagarika Banerjee; Tian Tian; Zhi Wei; Kristen N Peck; Natalie Shih; Ara A Chalian; Bert W O'Malley; Gregory S Weinstein; Michael D Feldman; James Alwine; Erle S Robertson
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

Review 5.  Prevalence of strongyloidiasis in Latin America: a systematic review of the literature.

Authors:  D Buonfrate; M A Mena; A Angheben; A Requena-Mendez; J Muñoz; F Gobbi; M Albonico; E Gotuzzo; Z Bisoffi
Journal:  Epidemiol Infect       Date:  2014-07-03       Impact factor: 4.434

6.  Distinct Microbial Signatures Associated With Different Breast Cancer Types.

Authors:  Sagarika Banerjee; Tian Tian; Zhi Wei; Natalie Shih; Michael D Feldman; Kristen N Peck; Angela M DeMichele; James C Alwine; Erle S Robertson
Journal:  Front Microbiol       Date:  2018-05-15       Impact factor: 5.640

7.  Fatal Strongyloides stercoralis hyperinfection syndrome in an alcoholic diabetic patient from México

Authors:  Elba G Rodríguez-Pérez; Alma Y Arce-Mendoza; Roberto Saldívar-Palacios; Kevin Escandón-Vargas
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

Review 8.  The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer.

Authors:  Sheetal Parida; Dipali Sharma
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-11       Impact factor: 10.680

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.